Donald Notman - 29 Aug 2024 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Chief Operating Officer and Chief Financial Officer
Signature
/s/ Donald Notman
Issuer symbol
OCUL
Transactions as of
29 Aug 2024
Net transactions value
$0
Form type
4
Filing time
03 Sep 2024, 16:08:59 UTC
Previous filing
06 Feb 2024
Next filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCUL Common Stock Award $0 +11,034 +5.6% $0.000000 208,988 29 Aug 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCUL Stock Option (Right to Buy) Award $0 +33,602 $0.000000 33,602 29 Aug 2024 Common Stock 33,602 $8.56 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On August 29, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.
F2 Includes 2,598 shares of common stock acquired under the 2014 Ocular Therapeutix, Inc. Employee Stock Purchase Plan on June 30, 2024.
F3 Vests over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.

Remarks:

Chief Operating Officer and Chief Financial Officer